ImCheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncology

10-10-2017 10:15

Marseille, France, 10 October 2017 – ImCheck Therapeutics, an emerging biopharmaceutical company developing a new generation of immunomodulatory antibodies against cancer and auto-immune diseases, announces a funding award of €930,000 from Bpifrance to contribute to the advancement of one of its novel immunotherapy program in cancer.

PDF-file 177.8kb

Dutch version - French version - German version